Details
| Original language | English |
|---|---|
| Pages (from-to) | 25-38 |
| Number of pages | 14 |
| Journal | European Journal of Health Economics |
| Volume | 10 |
| Issue number | 1 |
| Early online date | 1 Apr 2008 |
| Publication status | Published - Feb 2009 |
Abstract
Background: In Germany the heptavalent pneumococcal conjugate vaccine (PCV7) has been recommended as a general infant vaccination since 2006. Data from similar programmes in the USA have reported a reduction of pneumococcal diseases in both vaccinated and unvaccinated populations, suggesting herd immunity effects. This study analyses the cost-effectiveness of a general vaccination with PCV7 in Germany based on these findings. Methods: A Markov model adapts efficacy and herd immunity data to the German population. Further main model inputs are incidence, vaccination uptake, serotype distribution, case fatality rates, and vaccination and health-care costs. Results: A general vaccination with PCV7 would avoid about 232,000 pneumococcal infections and 1,879 premature deaths per year in Germany. From the health-care payer's perspective, direct cost savings would outweigh vaccination expenditures by a ratio of 1:1.16. The sensitivity analysis shows that these estimates are quite conservative. Conclusion: Based on the health-economic evaluation, the authors recommend the continuation of the general recommendation of PCV7 according to the 3 + 1 schedule within the German Statutory Health Insurance.
Keywords
- Germany, Herd immunity, Pneumococcal conjugate vaccine (PCV7), Pneumococcal disease
ASJC Scopus subject areas
- Economics, Econometrics and Finance(all)
- Economics, Econometrics and Finance (miscellaneous)
- Medicine(all)
- Health Policy
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: European Journal of Health Economics, Vol. 10, No. 1, 02.2009, p. 25-38.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects
AU - Claes, Christa
AU - Reinert, Ralf René
AU - Von Der Schulenburg, Johann Matthias Graf
N1 - Funding Information: This study was supported by an unrestricted educational grant from Wyeth Pharma, Münster, Germany.
PY - 2009/2
Y1 - 2009/2
N2 - Background: In Germany the heptavalent pneumococcal conjugate vaccine (PCV7) has been recommended as a general infant vaccination since 2006. Data from similar programmes in the USA have reported a reduction of pneumococcal diseases in both vaccinated and unvaccinated populations, suggesting herd immunity effects. This study analyses the cost-effectiveness of a general vaccination with PCV7 in Germany based on these findings. Methods: A Markov model adapts efficacy and herd immunity data to the German population. Further main model inputs are incidence, vaccination uptake, serotype distribution, case fatality rates, and vaccination and health-care costs. Results: A general vaccination with PCV7 would avoid about 232,000 pneumococcal infections and 1,879 premature deaths per year in Germany. From the health-care payer's perspective, direct cost savings would outweigh vaccination expenditures by a ratio of 1:1.16. The sensitivity analysis shows that these estimates are quite conservative. Conclusion: Based on the health-economic evaluation, the authors recommend the continuation of the general recommendation of PCV7 according to the 3 + 1 schedule within the German Statutory Health Insurance.
AB - Background: In Germany the heptavalent pneumococcal conjugate vaccine (PCV7) has been recommended as a general infant vaccination since 2006. Data from similar programmes in the USA have reported a reduction of pneumococcal diseases in both vaccinated and unvaccinated populations, suggesting herd immunity effects. This study analyses the cost-effectiveness of a general vaccination with PCV7 in Germany based on these findings. Methods: A Markov model adapts efficacy and herd immunity data to the German population. Further main model inputs are incidence, vaccination uptake, serotype distribution, case fatality rates, and vaccination and health-care costs. Results: A general vaccination with PCV7 would avoid about 232,000 pneumococcal infections and 1,879 premature deaths per year in Germany. From the health-care payer's perspective, direct cost savings would outweigh vaccination expenditures by a ratio of 1:1.16. The sensitivity analysis shows that these estimates are quite conservative. Conclusion: Based on the health-economic evaluation, the authors recommend the continuation of the general recommendation of PCV7 according to the 3 + 1 schedule within the German Statutory Health Insurance.
KW - Germany
KW - Herd immunity
KW - Pneumococcal conjugate vaccine (PCV7)
KW - Pneumococcal disease
UR - http://www.scopus.com/inward/record.url?scp=58149103494&partnerID=8YFLogxK
U2 - 10.1007/s10198-008-0098-1
DO - 10.1007/s10198-008-0098-1
M3 - Article
C2 - 18379830
AN - SCOPUS:58149103494
VL - 10
SP - 25
EP - 38
JO - European Journal of Health Economics
JF - European Journal of Health Economics
SN - 1618-7598
IS - 1
ER -